William Blair Investment Management LLC acquired a new position in Mesa Laboratories, Inc. (NASDAQ:MLAB – Free Report) in the third quarter, according to its most recent filing with the Securities and Exchange Commission. The institutional investor acquired 130,323 shares of the medical instruments supplier’s stock, valued at approximately $16,934,000.
Several other institutional investors have also recently modified their holdings of the company. Ranger Investment Management L.P. bought a new position in shares of Mesa Laboratories during the 2nd quarter valued at about $17,321,000. Diamond Hill Capital Management LLC Investment Advisor bought a new stake in Mesa Laboratories in the 2nd quarter worth approximately $15,507,000. Wasatch Advisors LP lifted its position in Mesa Laboratories by 125.8% in the 2nd quarter. Wasatch Advisors LP now owns 115,668 shares of the medical instruments supplier’s stock worth $11,515,000 after buying an additional 64,435 shares during the last quarter. Bank of New York Mellon Corp bought a new stake in Mesa Laboratories in the 2nd quarter worth approximately $4,540,000. Finally, Renaissance Technologies LLC boosted its stake in Mesa Laboratories by 802.9% in the first quarter. Renaissance Technologies LLC now owns 31,600 shares of the medical instruments supplier’s stock worth $2,794,000 after buying an additional 28,100 shares in the last quarter. 90.60% of the stock is currently owned by institutional investors.
Wall Street Analysts Forecast Growth
A number of brokerages have commented on MLAB. Weiss Ratings upgraded shares of Mesa Laboratories from a “hold (c-)” rating to a “hold (c)” rating in a research report on Thursday, October 8th. Wells Fargo & Company lifted their price target on shares of Mesa Laboratories from $94.00 to $110.00 and gave the stock an “equal weight” rating in a research note on Friday, August 14th. Jefferies Financial Group boosted their price objective on shares of Mesa Laboratories from $125.00 to $150.00 and gave the stock a “buy” rating in a report on Tuesday, November 10th. Finally, Wall Street Zen raised shares of Mesa Laboratories from a “buy” rating to a “strong-buy” rating in a research note on Saturday, October 3rd. One equities research analyst has rated the stock with a Buy rating and three have given a Hold rating to the company. According to data from MarketBeat, the company presently has an average rating of “Hold” and an average price target of $130.00.
Read Our Latest Stock Report on Mesa Laboratories
Mesa Laboratories Stock Performance
NASDAQ MLAB opened at $139.01 on Monday. The company has a 50-day simple moving average of $129.03 and a two-hundred day simple moving average of $106.25. Mesa Laboratories, Inc. has a 12-month low of $69.51 and a 12-month high of $144.35. The firm has a market cap of $781.24 million, a price-to-earnings ratio of 121.94 and a beta of 1.08. The company has a quick ratio of 1.39, a current ratio of 1.90 and a debt-to-equity ratio of 0.65.
Mesa Laboratories Announces Dividend
The business also recently announced a quarterly dividend, which will be paid on Tuesday, December 15th. Stockholders of record on Monday, November 30th will be paid a $0.16 dividend. This represents a $0.64 dividend on an annualized basis and a dividend yield of 0.5%. The ex-dividend date of this dividend is Monday, November 30th. Mesa Laboratories’s payout ratio is 56.14%.
Mesa Laboratories Profile
Mesa Laboratories, Inc. develops and manufactures instruments and consumable products used to monitor and control quality in life sciences and other regulated industries. Its offerings support activities such as sterilization and disinfection monitoring, laboratory testing, biopharmaceutical development, and equipment calibration. The company’s products include biological and chemical indicators, data loggers, calibration instruments, and tools used in clinical genomics and bioprocessing. Customers use these products to help verify processes, measure conditions, and meet quality requirements.
Featured Stories
- Five stocks we like better than Mesa Laboratories
- Intuitive Machines’ Business Is Taking Off—Will Its Stock Follow?
- The Next Big Thing May Not Be One Thing: Inside Lazard’s Megatrends ETF
- 3 Power and Grid Stocks That Could Keep Growing Even if AI Spending Slows
- Applied Materials Beats and Raises, But Investors Stay Unconvinced
Want to see what other hedge funds are holding MLAB? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Mesa Laboratories, Inc. (NASDAQ:MLAB – Free Report).
Receive News & Ratings for Mesa Laboratories Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Mesa Laboratories and related companies with MarketBeat.com's FREE daily email newsletter.
